Medoc

Medoc occupies a specialized position in neuro-diagnostic medical devices, focusing on quantitative sensory testing rather than broad hospital equipment or general-purpose diagnostics. Its differentiation is the combination of thermal, pressure, and vibratory assessment in one product family, allowing researchers and clinicians to examine multiple dimensions of sensory nerve function and pain response. The TSA2, TSA2 Air, Q-Sense CPM, AlgoMed, CoVAS, and VSA2 address distinct testing needs, while PATHWAY and CHEPS extend the platform into structured pain stimulation and evoked-response research. FDA approval, CE marking, and CSA certification support use across clinical and research settings, although the specific regulatory status of each product is not detailed here. Medoc’s target markets include pain medicine, neurology, diabetes-related sensory assessment, pharmaceutical studies, academic laboratories, and fMRI research. The company’s market identity is therefore best characterized as a focused, established supplier of pain and sensory-function measurement systems, with breadth across modalities as its clearest documented competitive attribute.

Medoc’s trajectory reflects sustained specialization rather than a clearly documented venture-style expansion cycle. Founded in 1990, the company has built a product portfolio around quantitative sensory testing and pain measurement, progressing from core thermal sensory analysis to complementary pressure, vibration, visual rating, conditioned pain modulation, and research-stimulation systems. The TSA2 and TSA2 Air address controlled thermal testing; AlgoMed measures pressure pain thresholds; VSA2 covers vibration sensation; and Q-Sense CPM supports assessment of endogenous pain inhibition. This breadth gives Medoc multiple entry points into clinical, academic, pharmaceutical, and fMRI workflows. The available company profile places its workforce in the 11–50 employee range and identifies two current featured positions, Amir Haiman and Udi Gafni, but does not provide a time series showing employee growth. No funding rounds, funding amounts, valuation, hiring campaign, product launch dates, or acquisition milestones are documented. Consequently, the strongest evidence of development is product and application diversification over more than three decades, not recent capital-driven scaling.